Rohtesh Mehta, MD
Hematology & Oncology · Houston, TXNPI 1669612123
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $14,421 of the $15,719 with a category attached, or 91.7%. CSL Behring accounts for 88.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $13,878 and has fallen 99.0% since, to $141 in 2025.
Across 21 payments — averaging $748.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$14K
- National Marrow Donor Program$2K
- Astellas Pharma US Inc$129
- Abbott$101
- Jazz Pharmaceuticals Inc.$39
- Johnson & Johnson$24
Across 91 payments — averaging $17,126 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.1M
- Sanofi US Services Inc.$231K
- Incyte Corporation$190K
- Bristol Myers Squibb$35K
- National Marrow Donor Program$28K
- Swedish Orphan Biovitrum AB$14K
- plus $6K from 3 others
What the payments were for
- Speaking & faculty fees$5754%
- Travel & lodging$14,42192%
- Food & beverage$4773%
- Education$1291%
- Entertainment$1171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 11 | $13,838 |
| National Marrow Donor Program | 4 | $1,588 |
| Astellas Pharma US Inc | 2 | $129 |
| Abbott | 2 | $101 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Johnson & Johnson | 1 | $24 |
How this compares
$15,719 in reported general payments places this provider in the 75th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.